In its Final Appraisal Report, the All Wales Medicines Strategy Group (AWMSG) has supported the restricted use within NHS Wales of ranolazine (Ranexa®) as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris, who remain symptomatic despite treatment with all other pharmacological anti-anginal therapies and where revascularisation has been considered and undertaken or is not considered appropriate Treatment should be initiated by a cardiologist.